Recombinant allergens: What does the future hold?

Valenta, Rudolf; Niespodziana, Katarzyna; Focke-Tejkl, Margit; Marth, Katharina; Huber, Hanspeter; Neubauer, A.; Niederberger, Verena

doi:10.1016/j.jaci.2011.02.016

Cited by 78 publications

(68 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This clearly demonstrates that most of the IgE-binding epitopes on Phl p 1 are located at the described hot spot and establishes the designed fragment as an IgE-hyporeactive protein with potential use as a safer alternative in specific immunotherapy. This approach to hypoallergen design is only one of many techniques available (11), and hypoallergenic Phl p 1 variants have previously been described both as B cell epitope-containing peptides (39,40) and as a mosaic version of Phl p 1 (41). There are, however, to our knowledge, no previous reports of potentially hypoallergenic fragments based on group 1 grass pollen allergens based on mutagenesis of IgE-binding epitopes, defined by human monoclonal IgE.…”

Section: Discussionmentioning

confidence: 99%

“…However, such natural extracts may be of varying quality, and potential pitfalls that must be considered include variations in allergen quantity, low stability, and poor immunogenicity of certain important allergen components as well as the presence of contaminations (9). Additionally, there is a risk of inducing lifethreatening side effects when using these extracts in immunotherapy (10,11). Recently, on account of the significant progress during the last two decades in characterization of the molecular nature of important allergens, safer alternatives to the natural extracts have been introduced, such as the use of recombinant allergens and socalled natural or recombinant hypoallergens.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Phl p 1–Specific Human Monoclonal IgE and Design of a Hypoallergenic Group 1 Grass Pollen Allergen Fragment

Levin

Rydnert

Källström

et al. 2013

The Journal of Immunology

View full text Add to dashboard Cite

Detailed understanding of how Abs of the IgE isotype interact with allergen at the onset of an allergic reaction is of great importance for deciphering mechanisms involved in the development of disease and may aid in the design of hypoallergenic variants. In this study, we have used a set of human monoclonal IgE Abs derived from the repertoires of allergic individuals, specific for the major timothy grass pollen allergen Phl p 1, to gain detailed information on the interaction between Abs and allergen. These allergen-specific IgE are to varying degrees cross-reactive toward both different allergen isoforms and various group 1 allergens originating from other grass species. The usage of human monoclonal IgE, as an alternative to polyclonal preparations or mouse Abs, allowed us to locate several important IgE-binding epitopes on the C-terminal domain of Phl p 1, all clustered to an IgE-binding “hot spot.” By introducing three mutations in the IgE-binding area of the C-terminal domain we were able to significantly reduce its reactivity with serum IgE. In conclusion, our study shows the great potential of using human monoclonal IgE as a tool for studies of the molecular interactions taking place during allergic responses. Furthermore, we present a novel IgE-hyporeactive fragment with the potential to be used as a safer hypoallergenic alternative in specific immunotherapy than the pollen extracts used today.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Phl p 1–Specific Human Monoclonal IgE and Design of a Hypoallergenic Group 1 Grass Pollen Allergen Fragment

Levin

Rydnert

Källström

et al. 2013

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Both recombinant allergen-diagnostic tests and immunotherapy lead to more personalized and stratified treatment of different allergic entities. Recombinant allergen-based vaccines have been developed and successfully evaluated for several respiratory allergen sources including food allergies [117][118][119][120]. The second approach for minimizing side effects and improves compliance is the usage of peptide immunotherapy that has been proven in many studies as effective in treating patients with different respiratory allergies [121].…”

Section: Future Perspectivesmentioning

confidence: 99%

Current Issues on Immunotherapy in Children

Djuric-Filipovic¹,

Živanović²,

Kostić³

et al. 2017

Allergen

View full text Add to dashboard Cite

Therapy of allergic diseases in children implicates avoidance of allergens, standard pharmacotherapy, and immunotherapy. Immunotherapy is the only treatment for allergic diseases with the ability to change the natural course of the disease, thus stopping its further progression as well as the development of new allergic diseases and new sensibilizations. The objective of this chapter is to give insight into the latest data on immunotherapy in treating children with allergic diseases. Methods: The study involved a search for relevant articles on the MEDLINE and PubMed up to 2017. Results: Numerous studies have shown that the sublingual application of allergen-specific immunotherapy is adequate, safe, and efficient in the therapy of immunoglobulin E (IgE)-mediated allergic diseases of the respiratory tract in children, but there are still some questions to be solved concerning the usage of SLIT in children younger than 5 years old, SLIT for polysensitized patients, duration of SLIT, long-lasting effects of SLIT. Conclusions: In order to improve the clinical efficacy of SLIT, we are looking for new routes of administration, new allergens, new protocols as well as combination of SLIT with other immune modulatory treatments.

show abstract

“…This preliminary study indicates that OIT may be a possible approach to treat birch pollen-related apple allergy. Novel concepts for allergy vaccines for SIT include the use of recombinant allergens instead of crude extracts containing a mixture of allergenic and non-allergenic proteins of an allergen source (Valenta et al, 2011). Although progress has been made to improve the quality and standardization of protein extracts the use of allergen extracts for SIT still bears some disadvantages.…”

Section: Future Concepts For Treatment Of Birch Pollen-related Food Amentioning

confidence: 99%

Birch Pollen-Related Food Allergy: An Excellent Disease Model to Understand the Relevance of Immunological Cross-Reactivity for Allergy

Subbarayal¹,

Geroldinger‐Simic²,

Bohle³

2012

Allergic Diseases - Highlights in the Clinic, Mechanisms and Treatment

View full text Add to dashboard Cite

Recombinant allergens: What does the future hold?

Cited by 78 publications

References 21 publications

Phl p 1–Specific Human Monoclonal IgE and Design of a Hypoallergenic Group 1 Grass Pollen Allergen Fragment

Phl p 1–Specific Human Monoclonal IgE and Design of a Hypoallergenic Group 1 Grass Pollen Allergen Fragment

Current Issues on Immunotherapy in Children

Birch Pollen-Related Food Allergy: An Excellent Disease Model to Understand the Relevance of Immunological Cross-Reactivity for Allergy

Contact Info

Product

Resources

About